ARMP - AMEX

Armata Pharmaceuticals, Inc.

ARMP·AMEX

$7.93

+0.13%

HealthcareBiotechnology

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$291.12M

EPS-4.8000

P/E Ratio-1.65

Earnings Date08/11/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Armata Pharmaceuticals, Inc. Earnings Call Transcripts

ARMP · AMEX

2018

1

Q2

N/A

Q3

N/A

Q4

N/A

2017

3

Q4

N/A

2016

2

Q3

N/A

Q4

N/A

2015

1

Q1

N/A

Q2

N/A

Q3

N/A

Related Guides

Blog Categories

Continue your ARMP research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.